These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38280268)

  • 21. Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD).
    Fragoso YD; Sousa NAC; Alves-Leon SV; Dias RM; Pimentel MLV; Gomes S; Goncalves MVM; Stella CV; Tauil CB; Anacleto A; Spessotto CV; Correa EC; Eboni ACB; Damasceno A; Damasceno B; Farinhas JGD; Mota RSS; Nogueira EGA; Pereira VCSR; Scorcine C; Bacon T; Kister I
    Mult Scler Relat Disord; 2019 Jan; 27():392-396. PubMed ID: 30504040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Progress in the treatment of neuromyelitis optica spectrum disorders related optic neuritis].
    Song HL; Xu QG; Wei SH
    Zhonghua Yan Ke Za Zhi; 2020 Jul; 56(7):539-543. PubMed ID: 32842338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum Disorder.
    Lotan I; Levy M
    Transfus Med Rev; 2022 Oct; 36(4):230-232. PubMed ID: 36153201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
    Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
    J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort.
    Rajput HM; Hassan M; Badshah M
    Mult Scler Relat Disord; 2023 Jun; 74():104656. PubMed ID: 37068371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder.
    Wingerchuk DM; Weinshenker BG; McCormick D; Barron S; Simone L; Jarzylo L
    J Manag Care Spec Pharm; 2022 Dec; 28(12-a Suppl):S3-S27. PubMed ID: 36427336
    [No Abstract]   [Full Text] [Related]  

  • 29. Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder.
    Hu Y; Sun Q; Yi F; Yao L; Tian Y; Tang H; Luo M; Xie N; Wang Z; Liao X; Zhou L; Xu H; Zhou Y
    Front Immunol; 2022; 13():1056944. PubMed ID: 36569880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of conventional MRI parameters in first spinal attacks of neuromyelitis optica spectrum disorder.
    Bonnan M; Debeugny S; Mejdoubi M; Cabre P
    Mult Scler; 2020 Apr; 26(4):468-475. PubMed ID: 30843448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort.
    Carnero Contentti E; López PA; Criniti J; Pettinicchi JP; Cristiano E; Patrucco L; Bribiesca Contreras E; Gómez-Figueroa E; Flores-Rivera J; Correa-Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Piedra Andrade JS; Galleguillos L; Tkachuk V; Nadur D; Daccach Marques V; Soto de Castillo I; Casas M; Cohen L; Alonso R; Caride A; Lana-Peixoto M; Rojas JI
    Eur J Neurol; 2022 Mar; 29(3):802-809. PubMed ID: 34799965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of therapeutic apheresis in patients with refractory neuromyelitis optica spectrum disorders: a single-center retrospective study.
    Zhang L; Zhuang Y; Liu X; Xu Q; Zhou L; Zou L; Jiang Y; Tian J; Yao H; Chi H; Qiu X; Yang T; Wang D; Yu Y
    Ann Palliat Med; 2021 Mar; 10(3):3105-3114. PubMed ID: 33752428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil.
    Lana-Peixoto MA; Talim NC; Pedrosa D; Macedo JM; Santiago-Amaral J
    Mult Scler Relat Disord; 2021 May; 50():102807. PubMed ID: 33609926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
    Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
    Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between Amerindian ancestry and neuromyelitis optica spectrum disorders (NMSOD) among patients in Midwestern Brazil.
    Alves CS; Santos FBC; Diniz DS
    Arq Neuropsiquiatr; 2022 May; 80(5):497-504. PubMed ID: 35766640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study.
    Ding J; Jiang X; Cai Y; Pan S; Deng Y; Gao M; Lin Y; Zhao N; Wang Z; Yu H; Qiu H; Jin Y; Xue J; Guo Q; Ni L; Zhang Y; Hao Y; Guan Y
    CNS Neurosci Ther; 2022 Oct; 28(10):1613-1623. PubMed ID: 35851754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination.
    Savransky A; Rubstein A; Rios MH; Vergel SL; Velasquez MC; Sierra SP; Marcarian G; Alba R; Pugliese AM; Tenembaum S
    Neurology; 2019 Nov; 93(22):e2065-e2073. PubMed ID: 31645471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma Exchange for Neuromyelitis Optica Spectrum Disorders in Chinese Patients and Factors Predictive of Short-term Outcome.
    Jiao Y; Cui L; Zhang W; Zhang Y; Wang W; Zhang L; Tang W; Jiao J
    Clin Ther; 2018 Apr; 40(4):603-612. PubMed ID: 29606515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies.
    Kim SH; Jang H; Park NY; Kim Y; Kim SY; Lee MY; Hyun JW; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33622675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.
    Takai Y; Kuroda H; Misu T; Akaishi T; Nakashima I; Takahashi T; Nishiyama S; Fujihara K; Aoki M
    Mult Scler Relat Disord; 2021 Apr; 49():102750. PubMed ID: 33524925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.